Clinical trials
Advanced Solid Tumor (Phase 1) clinical trials
Below are recruiting advanced solid tumor (phase 1) clinical trials, each written for real people, not researchers. We’re tracking 501 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07458347RecruitingPhase 1
Study of a new drug for advanced solid tumors with a KRAS mutation
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
Los Angeles, CaliforniaAges 18 years+ - NCT07864701RecruitingPhase 1/Phase 2
Study of an experimental drug for MYC-positive advanced cancers
This trial tests an experimental drug (JMBI-001) for people with advanced cancers that have a specific marker called MYC. It aims to see if the drug is safe and effective, possibly shrinking tumors or slowing their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05765851RecruitingPhase 1
A study of a new drug for advanced solid tumors with HER2
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
Sarasota, FloridaAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05539833RecruitingEarly Phase 1
TCR-T cell therapy for HLA-A2 positive solid tumors
This early-phase study tests a personalized immune-cell treatment (TCR-T cells) made from your own immune cells. You may qualify if you have a solid tumor that shows a specific target on tumor cells and your body type (HLA-A2) matches what the therapy needs.
Nanning, GuangxiAges 18–70 - NCT05204862RecruitingPhase 1/Phase 2
TU2218 drug with PD-1 therapy for advanced solid tumors
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
San Antonio, TexasAges 18 years+ - NCT05823285RecruitingPhase 1
Study of QLS31903 for advanced solid tumors
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05911464RecruitingPhase 1
Study drug HS-10386 for advanced solid tumor cancers
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05923008RecruitingPhase 1/Phase 2
Study of IBI130 for advanced solid tumors
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Birtinya, QueenslandAges 18 years+ - NCT05801237RecruitingPhase 1/Phase 2
Study of two drugs for advanced solid tumors
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
ShanghaiAges 18–75 - NCT02013336RecruitingPhase 1
Two-drug study for returning childhood solid tumors
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
Cincinnati, OhioAges 1–20 - NCT06225856RecruitingPhase 1
YY201 for advanced solid tumors and blood cancers
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06245330RecruitingPhase 1/Phase 2
Study of AST-001 for advanced solid tumors
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
Changchun, JinlinAges 18–70 - NCT06246071RecruitingPhase 1
TYK-00540 for adults with solid tumors
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
HefeiAges 18 years+ - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06374173RecruitingPhase 1
Study of TGI-6 for advanced solid tumors
This study tests a new drug called TGI-6 in people with advanced solid tumors, including colorectal cancer and other cancers that have a specific marker (B7-H6). The goal is to see if it is safe and effective for those who have run out of standard treatment options.
BeijingAges 18 years+ - NCT06403735RecruitingPhase 1
Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Guangzhou, GuangdongAges 18 years+ - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT05532696RecruitingPhase 1/Phase 2
Testing ABT-101 for advanced solid tumors and HER2-mutant lung cancer
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
TaichungAges 18 years+ - NCT07824934RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, HEC-921, given alone or with other cancer treatments for people with advanced solid tumors. It may be an option for those who have tried standard treatments or who have a specific marker on their tumor.
ShanghaiAges 18 years+ - NCT07819136RecruitingPhase 1/Phase 2
REC-7735 for people with advanced solid tumors
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
Grand Rapids, MichiganAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor (phase 1)?
- Yes. Clin2 currently lists 501 recruiting advanced solid tumor (phase 1) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor (phase 1) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor (phase 1) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.